Afuresertib - CAS 1047644-62-1
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Afuresertib
Catalog Number:
1047644-62-1
Synonyms:
GSK-2110183; GSK 2110183; GSK2110183; GSK-2110183B; GSK 2110183B; GSK2110183B; Afuresertib.
CAS Number:
1047644-62-1
Description:
Afuresertib, also known as GSK2110183,  is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2110183 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
COA:
Inquire
MSDS:
Inquire
Targets:
Akt
Current Developer:
GlaxoSmithKline.
Chemical Structure
CAS 1047644-62-1 Afuresertib

Related Akt Products


CAS 1047635-80-2 GSK2141795 hydrochloride

GSK2141795 hydrochloride
(CAS: 1047635-80-2)

GSK2141795 Hcl is a potent and selective pan-Akt inhibitor with IC50s of 180/328/38 nM for Akt1/Akt2/Akt3 respectively.

ARQ-092
(CAS: 1313881-70-7)

ARQ-092, also called as Miransertib, is an oral activie, potent and selective AKT inhibitor with IC50= 5.0 nM against AKT1, 4.5 nM against AKT2 and 16 nM agains...

CAS 1191951-57-1 PHT-427

PHT-427
(CAS: 1191951-57-1)

PHT-427 is an AKT inhibitor that inhibits AKT and PDPK1 at low micromolar concentrations in numerous cancer cell lines and exhibits good oral anti-tumor activit...

CAS 612847-09-3 AKT inhibitor VIII

AKT inhibitor VIII
(CAS: 612847-09-3)

Akt Inhibitor VIII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and...

CAS 842148-40-7 AKT Kinase Inhibitor

AKT Kinase Inhibitor
(CAS: 842148-40-7)

AKT Kinase Inhibitor is a Akt Kinase Inhibitor.

CAS 1056901-62-2 AT13148

AT13148
(CAS: 1056901-62-2)

AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT...

CAS 1047644-62-1 Afuresertib

Afuresertib
(CAS: 1047644-62-1)

Afuresertib, also known as GSK2110183,  is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineo...

MK-2206 hydrochloride
(CAS: 1032349-77-1)

MK-2206 hydrochloride is the hydrochloride form of MK-2206, which is an allosteric inhibitor of Akt and an orally bioavailable allosteric inhibitor of the serin...

CAS 893422-47-4 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1
(CAS: 893422-47-4)

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is depend...

CAS 1032349-93-1 MK-2206

MK-2206
(CAS: 1032349-93-1)

MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/...

SC79
(CAS: 305834-79-1)

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

CAS 522-17-8 Deguelin

Deguelin
(CAS: 522-17-8)

Deguelin is a naturally occurring rotenoid, is known to be an Akt inhibitor and to have an anti-tumor effect on several cancers.

CAS 1431697-86-7 AT7867 dihydrochloride

AT7867 dihydrochloride
(CAS: 1431697-86-7)

AT7867 also inhibits structurally related AGC kinases p70S6K and PKA with IC50 of 20 nM and 85 nM, respectively. AT7867 shows ATP-competitive activity to Akt2 w...

CAS 1396257-94-5 GDC-0068 dihydrochloride

GDC-0068 dihydrochloride
(CAS: 1396257-94-5)

Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69...

CAS 857531-00-1 AT7867

AT7867
(CAS: 857531-00-1)

AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside th...

CAS 1143532-39-1 AZD-5363

AZD-5363
(CAS: 1143532-39-1)

AZD5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD5363 binds to ...

CAS 1032350-13-2 MK-2206·2HCl

MK-2206·2HCl
(CAS: 1032350-13-2)

MK2206 is a Akt inhibitor, is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential anti...

CAS 1001264-89-6 Ipatasertib

Ipatasertib
(CAS: 1001264-89-6)

Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplas...

CAS 871361-88-5 SC66

SC66
(CAS: 871361-88-5)

SC66 is a novel and potent AKT inhibitor, which reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in...

CAS 1047634-65-0 Uprosertib

Uprosertib
(CAS: 1047634-65-0)

Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potentia...

Reference Reading


1.The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.
Spencer A1, Yoon SS2, Harrison SJ3, Morris SR4, Smith DA4, Brigandi RA5, Gauvin J4, Kumar R5, Opalinska JB5, Chen C6. Blood. 2014 Oct 2;124(14):2190-5. doi: 10.1182/blood-2014-03-559963. Epub 2014 Jul 29.
The PI3K/AKT pathway is constitutively active in hematologic malignancies, providing proliferative and antiapoptotic signals and possibly contributing to drug resistance. We conducted an open-label phase 1 study to evaluate the maximum tolerated dose (MTD), safety, pharmacokinetics, and clinical activity of afuresertib-an oral AKT inhibitor-in patients with advanced hematologic malignancies. Seventy-three patients were treated at doses ranging from 25 to 150 mg per day. The MTD was established at 125 mg per day because of 2 dose-limiting toxicities in the 150-mg cohort (liver function test abnormalities). The most frequent adverse events were nausea (35.6%), diarrhea (32.9%), and dyspepsia (24.7%). Maximum plasma concentrations and area under the plasma concentration-time curves from time 0 to 24 hours were generally dose proportional at > 75-mg doses; the median time to peak plasma concentrations was 1.5 to 2.5 hours post dose, with a half-life of approximately 1.
2.Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW1, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, Orford K, Aktan G, Ferron-Brady G, Ibrahim N, Gauvin J, Motwani M, Cornfeld M. Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9. doi: 10.1007/s00280-014-2615-5. Epub 2014 Nov 25.
PURPOSE: To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.